Published on:

April 2012 Medication Label Changes

Last month brought changes to forty-three (43) medical product labels (slightly up from 39 changes in March), with changes to the prescribing information to include any of the following areas: boxed warnings, contraindications, warnings, precautions, adverse reactions, patient package insert, and medication guide.

For a complete detailed accounting of the label changes, please refer to the summary of meds. By clicking onto the drug name, you can view the detailed summary, which will identify the safety labeling section, the revised subsection, and a brief summary of the new or modified safety information.

The following medications have been affected:

Aceon (Perindopril Erbumine)
Altace (Ramipril)
Atacand (Candesartan Cilexetil)
Sporanox (Itraconazole)
Zortress (Everolimus)
Advicor (Niacin Extended-release/Lovastatin)
Altoprev (Lovastatin Extended-release)
Amturnide (Aliskiren, amlodipine, and Hydrochlorothiazide)
Premarin (Conjugated Estrogens, USP)
Tekamlo (Aliskiren and amlodipine)
Tekturna (Aliskiren)
Tekturna HCT (Aliskiren and Hydrochlorothiazide)
Vagifem (Estradiol)
Valturna (Aliskiren and Valsartan)
Viracept (nelfinavir mesylate)
Beyaz (Drospirenone and Ethinyl Estradiol and Levomefolate Calcium)
Cimzia (Certolizumab Pegol)
Krystexxa (Pegloticase)
Levaquin (Levofloxacin)
Levemir (Insulin Detemir [rDNA origin])
Neupro (Rotigotine)
Nutropin (Somatropin [rDNA origin])
Prandimet (Repaglinide and Metformin HCL)
Safyral (Drospirenone and Ethinyl Estradiol and Levomefolate Calcium)
Sutent (Sunitinib Malate)
Synagis (palivizumab)
Tarceva (Erlotinib)
Victoza (liraglutide [rDNA])
Votrient (Pazopanib)
Xgeva (Denosumab)
Yasmin(Drospirenone and Ethinyl Estradiol)
Yaz (Drospirenone and Ethinyl Estradiol)
Zegerid (Omeprazole and Sodium Bicarbonate)